Sun Pharma halts distribution and recalls multiple eye-drop products as a precaution
Sun Pharma has told distributors to immediately stop billing and return existing stocks of several eye-drop brands, including Depopred, Brinolar and Toba-F. The company said it is following regulatory requirements and working to restore availability for patients.
Sun Pharma has instructed distributors to immediately stop billing and return existing stocks of multiple eye-drop products as a precautionary withdrawal. The company said it is following regulatory requirements and working to restore product availability for patients.
Why this matters
The eye-drop distribution halt follows Sun Pharma's recent Q1FY27 update, when profit rose 27% and India formulations grew 16%, adding a product-availability issue to its growth narrative.
Retail-company signals are accelerating, up 220650% QoQ.